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Abstract
Background:  Coxibs are claimed to be cost-effective drugs and reduced prescription of
gastroprotective agents is assumed to be one of their major benefits. Real life prescription of these
drugs may be substantially different than that considered in pharmacoeconomic analyses or claimed
by drug companies, yet. Our objective was to evaluate whether coxibs were associated with
reduced prescription of gastro-protective agents (GPAs, specifically proton pump inhibitors, H2
blockers and misoprostol) compared to non selective NSAIDs.
Methods: A record-linkage study was performed using 2001 outpatient prescription data from the
province of Modena (about 632,000 inhabitants, in Northern Italy). Logistic regression was used to
calculate the odds ratio of GPA prescription for coxib and non-selective NSAID adult users (> 14
years). Three categories of users were further investigated: "acute", "chronic and "incident or new".
Main outcome measures were same-day co-prescription and 30 days prescription of GPAs in
coxibs and non selective NSAIDs users. To limit selection bias, data were adjusted for age, sex,
DDD of coxibs and non selective NSAIDs received during 2001, DDD of GPAs and (for non-
incident users) DDD of NSAIDs received during the previous 4 years
Results: Same day co-prescription rates were similar considering the overall population and
"acute" users. Chronic coxibs users instead showed higher co-prescription rates than chronic
NSAIDs users (OR = 1.2, p < 0.05). GPA prescription within thirty days was also higher among all
subgroups of coxibs users (OR ranging from 1.6 to 2.0, p < 0.001).
Conclusion:  Assumptions made in pharmacoeconomic analyses on coxibs (lower GPA
prescription associated with coxibs use) may be overly optimistic. Claims made through cost-
effectiveness data should be carefully interpreted, and mechanisms for attributing drug prices
revised accordingly.
Background and objective
Pharmacoeconomic analyses are used to highlight poten-
tial advantages of new drugs over older ones by showing,
in general, that higher effectiveness and/or less frequent
side effects may be worth the (generally) higher cost.
Assumptions and findings from these analyses may not
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reflect everyday practice yet, as real life prescription and
use of marketed drugs may be different from that
observed in Randomised Controlled Trials and/or
assumed in economic models.
Coxibs were found to have higher gastrointestinal tolera-
bility than traditional NSAIDs, but their overall safety pro-
file is controversial in light of cardiovascular risks
demonstrated for rofecoxib, celecoxib and (in post surgi-
cal patients) for parecoxib and valdecoxib [1-5]. These are
claimed to be cost-effective drugs especially in high risk
patients, and especially on the ground of reduced co-pre-
scription of gastro-protective agents (GPAs), as some cost-
effectiveness analyses stated [6-9] and pharmaceutical
companies proposed [10] (especially considering patients
at high risk of gastrointestinal bleeding). NSAIDs prescrip-
tion and co-prescription of GPAs are relevant to decision
makers: GPAs and anti-inflammatory drugs prescribed
within the National Health System (NHS) account for
7.1% and 4.5% of the Italian gross pharmaceutical
expenditure, respectively [11].
In Italy, the co-prescription of GPAs and coxibs is theoret-
ically not allowed, since GPAs prescription should be jus-
tified – on the prescription itself – on clinical grounds
other than the use of a coxib. Often in practice, doctors do
not follow this rule and co-prescribe GPAs with coxibs.
Our purpose was to explore whether coxibs are associated
with (at least)reduced co-prescription rates of GPAs in
comparison with traditional NSAIDs, thus testing one of
the main assumptions of pharmacoeconomic analyses on
these drugs.
Methods
We performed a record-linkage study using 2001 NHS
prescription data from an electronic database of outpa-
tient prescriptions of the province of Modena (about
632,000 inhabitants, in Northern Italy). Specifically, we
analysed prescriptions of GPAs (proton pump inhibitors,
H2 blockers and misoprostol), occurring either the same
day of, or within 30 days since (assumed as an adequate
time window for acute gastrotoxic events), prescription of
oral NSAIDs and/or coxibs. Information about time and
amount of prescribing, and age and sex of recipients were
collected. All these prescriptions are free of charge within
our Regional Health System.
Logistic regression was used to calculate the odds ratio of
GPA prescription for coxib and non-selective NSAID
users, excluding the pediatric population (< 14 years old).
Specific subgroups were investigated: "acute" users,
defined as those who received less than 60 Defined Daily
Doses (DDD) of traditional NSAIDs or coxibs during
2001; "chronic" users, as those who received at least 60
DDD of any anti-inflammatory drug during 2001 (96% of
them had received at least a two-pieces repeated prescrip-
tion over four months); "incident"/new users, as those
who had never been prescribed any NSAIDs during the
previous four years; in this latter group, we further distin-
guished those who had never been prescribed GPAs in the
same period (theoretically, at lower risk of assuming GPAs
in the observational period). In addition to considering
those subgroups, further attention was given to limit
selection bias (prescription of coxibs to patients at higher
risk of GI bleeding) by adjusting for age, sex, DDD of cox-
ibs and non selective NSAIDs received during 2001, DDD
of GPAs and [*] (for non-incident users) DDD of NSAIDs
received during the previous 4 years.
Results
In 2001, coxibs and oral non-selective NSAIDs were pre-
scribed to 3.4% and 9.2% of the adult population of the
study area, respectively. The vast majority of patients
treated with these drugs (73.5%) were acute users (less
than 60 DDD/year, with an average of 26 DDD); almost
no difference existed in the proportion of coxibs and non-
selective NSAIDs acute users. About 50% of coxibs and
NSAIDs users were "incident" users (subjects having not
received any NSAIDs in the previous four years).
GPAs were co-prescribed to 6.1% of individuals receiving
anti-inflammatory drugs, and 5.7% were prescribed GPAs
within 30 days (Table 1). The majority (73.3%) of gastro-
protected patients received proton pump inhibitors,
whereas 26.8% and 5.2% received H2 receptor antagonists
and misoprostol, respectively (some patients have taken
different classes of GPAs at different times). Table 2 shows
adjusted odds ratio of GPA prescription for coxib and non
selective NSAIDs users. Co-prescription of GPAs was sim-
ilar for coxib and non-selective NSAID users in all patients
subgroups, except in incident users (higher GPAs prescrip-
tion in coxib users; OR = 1.2, p = 0.03). Conversely, pre-
scription of GPAs within 30 days was always higher –
Table 1: Prescription of GPAs (%) according to type of NSAIDs used
User category N. users Same day GPA co-prescription Prescription of GPA within 30 gg
Only traditional NSAIDs 50,204 2400 (4.8%) 2018 (4.0%)
Only coxibs 13,339 829 (6.2%) 888 (6.7%)
Both traditional NSAIDs and 
coxibs
8,058 1153 (14.3%) 1172 (14.5%)
Total 71,601 4382 (6.1%) 4078 (5.7%)Cost Effectiveness and Resource Allocation 2006, 4:4 http://www.resource-allocation.com/content/4/1/4
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across all patients' subgroups – for coxib compared to
non-selective NSAID users (ORs range from 1.6 to 2.0).
Discussion
Even with the intrinsic limitations of such a record-link-
age study (residual confounding; analysing only prescrip-
tions and not diagnoses), our example suggests that
coxibs may not be associated with reduced prescription of
GPAs – as manufacturers claim or imply – and that pre-
ventive (and selective) co-prescription of GPAs and coxibs
to those at higher risk of bleeding is not necessarily the key
to the whole story. Unexpectedly, patients who received
coxibs (supposed to be less gastrotoxic than traditional
NSAIDs) were more "at risk" to be prescribed GPAs within
30 days. Moreover incident NSAIDs users, supposed to be
less at risk of being prescribed GPAs (thus being less
affected by selection bias), were actually co-prescribed
GPAs more often the same day. This could mean that they
are either not safer than traditional NSAIDs (in terms of
gastrointestinal tolerability) or that anyway prescribers do
not reduce co-prescription of GPA. Although gastrointes-
tinal tolerability of coxibs is controversial, both RCT and
observational studies exclude that coxibs are more gastro-
toxic [12]. On the other side, evidence of higher gastroin-
testinal tolerability from RCTs is only available for
rofecoxib, but this drug has been withdrawn from the
market worldwide on September 2004 for evidence of
increasing cardiovascular risk.
Is it true that more expensive drugs eventually lower pre-
scription costs? Such an assumption is often made in
pharmacoeconomic analyses and has also been made in
economic analysis on coxibs. The purpose of our study
was to explore this assumption and our data, consistent
with those of previous researches [12,13] (but adding fur-
ther insight on drug prescriptions in acute, chronic and
incident users) show it may not be true in practice. Atti-
tudes towards "defensive" medicine could be a key deter-
minant, so that some doctors may consider this
prescribing behaviour safer, also considering the high tol-
erability of proton pump inhibitors. This may indirectly
result into prescribing coxibs plus GPAs, even if in Italy
this represents an unlicensed use, and despite lacking evi-
dence from RCTs on the higher safety profile of this com-
bination compared to coxib alone or to traditional
NSAIDs plus GPAs. In this regard, no evidence-based
guideline recommends such a combination as a therapeu-
tic alternative to NSAIDs/GPA combination. In actual
practice, doctors may also be influenced by patients and
especially drug representatives [14,15] in using the (sup-
posedly) best and more expensive (but without a solid
base of evidence) drugs.
Conclusion
We think more research and debate should be made on
methods used in pharmacoeconomics – which may be
used to affect decisions on drug reimbursement and prices
[16] – and on how to best integrate effectiveness and eco-
nomics data. We suggest that observational data should
be evaluated while developing a pharmacoeconomic
model if resource consumption is at stake, to get a more
realistic "flavour" of drug utilization in clinical practice
and related economic implications. When RCT data on
resource consumption are available, these should at least
be compared to observational data – evaluating their
overall consistency – before incorporating them in eco-
nomic models. Pharmacoeconomic analyses may then
lose some of their appeal, especially for manufacturers,
[17] but they would probably be more useful in providing
decision makers with reliable data.
Table 2: Odds ratio (95% CI) of GPA prescription (proton pump inhibitors, H2 blockers and misoprostol) – occurring the same day or 
within 30 days – for coxib vs. oral non selective NSAIDs adult users
Adjusted # odds ratio (95% CI) of GPA prescription (coxib vs. non selective 
NSAIDs users)
Patients' profile N. % Co-prescription of GPAs (same day) Prescription of GPAs within 30 days
No NSAIDs and/or GPAs in the previous 4 years 30,658 42.8 1.1 (0.9–1.3) 1.7 (1.3–2.1) °
No NSAIDs in the previous 4 years 36,077 50.4 1.2 (1.0–1.4) * 1.6 (1.3–1.8) °
Acute patients † 52,608 73.5 1.3 (1.0–1.7) 1.7 (1.3–2.3) °
Chronic patients ‡ 18,993 26.5 1.2 (1.0–1.5) * 1.7 (1.3–2.3) °
All patients 71,601 100 1.1 (1.0–1.2) 2.0 (1.8–2.2) °
† Individuals who had been prescribed less than 60 DDD of NSAIDs (either selective or non selective) during 2001
‡ Individuals who had been prescribed at least 60 DDD of NSAIDs (either selective or non selective) during 2001
# Adjusted for age, sex, DDD of coxib and NSAID received during 2001, and (not for incident patients) DDD of GPAs and NSAIDs received during 
the previous 4 years
* p < 0.05
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